Pirsalehi Ali, Soleimani Masoud, Hajifathali Abbas, Sadeghi Behnam, Farhadihosseinabadi Behrouz, Akhlaghi Sedigheh Sadat, Roshandel Elham
Department of Internal Medicine School of Medicine Shahid Beheshti University of Medical Sciences Tehran Iran.
Hematopoietic Stem Cell Research Center Shahid Beheshti University of Medical Sciences Tehran Iran.
Clin Case Rep. 2022 May 16;10(5):e05851. doi: 10.1002/ccr3.5851. eCollection 2022 May.
We are going through the greatest global health crisis of the last decades, the coronavirus disease 2019 (COVID-19) pandemic. It may cause morbidity and mortality in some cases, and there is no therapeutic approach with reproducible and favorable outcomes. As clinical manifestations differ from patient to patient, any report regarding clinical symptoms has been beneficial for early detection and treatment. Due to the immunomodulatory effect of mesenchymal stem cells (MSCs), MSCs-based therapy has been approved to be one of the therapeutic strategies for COVID-19 management. For the first time in the literature, we reported generalized lymphadenopathy with fever and no sign of respiratory distress in a 16-year-old patient with confirmed COVID-19 infection as the main clinical signs. We also introduce decidual stromal cells as a potential immunomodulatory treatment for COVID-19-infected patients.
我们正在经历过去几十年来最严重的全球健康危机——2019冠状病毒病（COVID-19）大流行。在某些情况下，它可能导致发病和死亡，并且目前尚无具有可重复且良好疗效的治疗方法。由于临床表现因人而异，任何有关临床症状的报告都有助于早期发现和治疗。鉴于间充质干细胞（MSCs）的免疫调节作用，基于MSCs的疗法已被批准作为COVID-19治疗的策略之一。在文献中，我们首次报告了一名确诊COVID-19感染的16岁患者以发热和无呼吸窘迫迹象的全身性淋巴结肿大作为主要临床体征。我们还介绍了蜕膜基质细胞作为COVID-19感染患者潜在的免疫调节治疗方法。
